Clinical trial
Phase II Study of Bevacizumab and Erlotinib in Elderly Patients With Advanced Non-Small Lung Cancer
NCT00553800 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Bevacizumab and Erlotinib in Elderly Patients With Advanced Non-Small Lung Cancer
- Lead sponsor
- Fox Chase Cancer Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 5, 2007
- Completion date
- June 1, 2011
- Enrollment
- 32 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.